Citation Impact
Citing Papers
The gut microbiota influences blood-brain barrier permeability in mice
2014 Standout
Age at onset of mental disorders worldwide: large-scale meta-analysis of 192 epidemiological studies
2021 Standout
Schizophrenia risk from complex variation of complement component 4
2016 StandoutNature
Altered gene expression in the superior temporal gyrus in schizophrenia
2008
Interacting with nature improves cognition and affect for individuals with depression
2012 Standout
Age of onset of mental disorders: a review of recent literature
2007 Standout
The Efficacy of Cognitive Behavioral Therapy: A Review of Meta-analyses
2012 Standout
Development of social functioning in preschizophrenia children and adolescents: A systematic review.
2008
RIM1α and Interacting Proteins Involved in Presynaptic Plasticity Mediate Prepulse Inhibition and Additional Behaviors Linked to Schizophrenia
2010 StandoutNobel
Progressive brain structural changes mapped as psychosis develops in ‘at risk’ individuals
2009
Short-chain fatty acid fermentation products of the gut microbiome: implications in autism spectrum disorders
2012
Oxidative stress, aging, and diseases
2018 Standout
Emotion-regulation strategies across psychopathology: A meta-analytic review
2009 Standout
Neurofunctional correlates of vulnerability to psychosis: A systematic review and meta-analysis
2007
Early Intervention in Psychosis
2015
Chronic inflammation in the etiology of disease across the life span
2019 Standout
Oxidative Stress Hypothesis in Alzheimer's Disease
1997 Standout
Outreach and support in South London (OASIS), 2001–2011: Ten years of early diagnosis and treatment for young individuals at high clinical risk for psychosis
2012
Cognitive impairment and in vivo metabolites in first-episode neuroleptic-naive and chronic medicated schizophrenic patients: A proton magnetic resonance spectroscopy study
2006
Schizophrenia
2009 Standout
Better reporting of interventions: template for intervention description and replication (TIDieR) checklist and guide
2014 Standout
Medical treatment overview
2011
Enteric Bacterial Metabolites Propionic and Butyric Acid Modulate Gene Expression, Including CREB-Dependent Catecholaminergic Neurotransmission, in PC12 Cells - Possible Relevance to Autism Spectrum Disorders
2014
Expression of disrupted-in-schizophrenia-1, a schizophrenia-associated gene, is prominent in the mouse hippocampus throughout brain development
2004
WHO World Mental Health Surveys International College Student Project: Prevalence and distribution of mental disorders.
2018 Standout
World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, Part 1: Update 2012 on the acute treatment of schizophrenia and the management of treatment resistance
2012
The Science of Stroke: Mechanisms in Search of Treatments
2010 Standout
Proton magnetic resonance spectroscopy in subjects at risk for schizophrenia
2006
Omega-3 Polyunsaturated Fatty Acids and Cardiovascular Diseases
2009 Standout
Adolescents at ultra-high risk for psychosis with and without 22q11 deletion syndrome: A comparison of prodromal psychotic symptoms and general functioning
2012
Tau-mediated iron export prevents ferroptotic damage after ischemic stroke
2017
Elevated Striatal Dopamine Function Linked to Prodromal Signs of Schizophrenia
2009
Complement: a key system for immune surveillance and homeostasis
2010 Standout
Metagenomic biomarker discovery and explanation
2011 Standout
Metabolic changes in schizophrenia and human brain evolution
2008 StandoutNobel
The role of the posterior cingulate cortex in cognition and disease
2013 Standout
The relationship between neurocognition and social cognition with functional outcomes in schizophrenia: A meta-analysis
2010 Standout
Preventive Treatments for Psychosis: Umbrella Review (Just the Evidence)
2019
Prediction of Psychosis in Youth at High Clinical Risk
2008
The enteric bacterial metabolite propionic acid alters brain and plasma phospholipid molecular species: further development of a rodent model of autism spectrum disorders
2012
The Dopamine Hypothesis of Schizophrenia: Version III--The Final Common Pathway
2009 Standout
Early detection and intervention evaluation for people at risk of psychosis: multisite randomised controlled trial
2012
Evidence for glutamatergic neuronal dysfunction in the prefrontal cortex in chronic but not in first-episode patients with schizophrenia: a proton magnetic resonance spectroscopy study
2004
N-Acetylaspartate in the CNS: From neurodiagnostics to neurobiology
2007 Standout
Cognitive performance is related to cortical grey matter volumes in early stages of schizophrenia: A population-based study of first-episode psychosis
2009
Rethinking schizophrenia
2010 StandoutNature
The Role of Short-Chain Fatty Acids From Gut Microbiota in Gut-Brain Communication
2020 Standout
Free radicals, antioxidant defense systems, and schizophrenia
2013
Power failure: why small sample size undermines the reliability of neuroscience
2013 Standout
Group VIA Ca2+-independent phospholipase A2 (iPLA2β) and its role in β-cell programmed cell death
2010
The role of short-chain fatty acids in microbiota–gut–brain communication
2019 Standout
Editor's Introduction: The Empirical Status of the Ultra High-Risk (Prodromal) Research Paradigm
2007
Establishing a clinical service to prevent psychosis: What, how and when? Systematic review
2021
Mental health literacy: Empowering the community to take action for better mental health.
2011 Standout
Social functioning as an outcome measure in schizophrenia studies
2007
The HPA axis in major depression: classical theories and new developments
2008 Standout
Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence
2004 Standout
Autism
2013 Standout
N-methyl-d-aspartate antibody encephalitis: temporal progression of clinical and paraclinical observations in a predominantly non-paraneoplastic disorder of both sexes
2010 Standout
Adhesio interthalamica alterations in schizophrenia spectrum disorders: A systematic review and meta-analysis
2011
Effects of acute metabolic stress on the dopaminergic and pituitary–adrenal axis activity in patients with schizophrenia, their unaffected siblings and controls
2007
Very long-chainn-3 fatty acids and human health: fact, fiction and the future
2017
The Antecedents of Schizophrenia: A Review of Birth Cohort Studies
2008
Serotonin, tryptophan metabolism and the brain-gut-microbiome axis
2014 Standout
Mind-altering microorganisms: the impact of the gut microbiota on brain and behaviour
2012 Standout
Progressive Changes in the Development Toward Schizophrenia: Studies in Subjects at Increased Symptomatic Risk
2007
NLRP3 inflammasome activation: the convergence of multiple signalling pathways on ROS production?
2010 Standout
Why do many psychiatric disorders emerge during adolescence?
2008 Standout
Ferroptosis: mechanisms, biology and role in disease
2021 Standout
An automated tool for detection of FLAIR-hyperintense white-matter lesions in Multiple Sclerosis
2011 Standout
Gut microbiome and magnetic resonance spectroscopy study of subjects at ultra-high risk for psychosis may support the membrane hypothesis
2018
22q11.2 deletion syndrome
2015 Standout
Progressive Reduction in Cortical Thickness as Psychosis Develops: A Multisite Longitudinal Neuroimaging Study of Youth at Elevated Clinical Risk
2014
Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis
2013 Standout
Gray matter abnormalities in subjects at ultra-high risk for schizophrenia and first-episode schizophrenic patients compared to healthy controls
2009
Prescription omega-3 fatty acids and their lipid effects: physiologic mechanisms of action and clinical implications
2008
Oxidative Stress: Harms and Benefits for Human Health
2017 Standout
Eugenol as an anti-stress agent: Modulation of hypothalamic–pituitary–adrenal axis and brain monoaminergic systems in a rat model of stress
2010
Preventing the Second Episode: A Systematic Review and Meta-analysis of Psychosocial and Pharmacological Trials in First-Episode psychosis
2009
Spatiotemporal distribution pattern of white matter lesion volumes and their association with regional grey matter volume reductions in relapsing‐remitting multiple sclerosis
2010
Alternative Complement Pathway in Schizophrenia
2010
Complementary and Alternative Medicine in Autism: An Evidence-Based Approach to Negotiating Safe and Efficacious Interventions with Families
2010
Lipid Oxidation and Peroxidation in CNS Health and Disease: From Molecular Mechanisms to Therapeutic Opportunities
2009
Eugenol—From the Remote Maluku Islands to the International Market Place: A Review of a Remarkable and Versatile Molecule
2012 Standout
The Epidemiology of Depression Across Cultures
2013 Standout
White Matter Alterations in Early Stages of Schizophrenia: A Systematic Review of Diffusion Tensor Imaging Studies
2013
The clinical value of salivary biomarkers for periodontal disease
2009
Interventions for prodromal stage of psychosis
2019
Cognitive and Psychiatric Predictors to Psychosis in Velocardiofacial Syndrome: A 3-Year Follow-Up Study
2010
Citalopram versus other anti-depressive agents for depression
2012
The Descriptive Epidemiology of Commonly Occurring Mental Disorders in the United States
2008
Oxidative stress in schizophrenia - focusing on the main markers.
2011
Rebooting Psychotherapy Research and Practice to Reduce the Burden of Mental Illness
2011
Probability of Transition to Psychosis in Individuals at Clinical High Risk
2021
Marine natural products
2018 Standout
Ferroptosis as a target for protection against cardiomyopathy
2019 Standout
Adolescence: a foundation for future health
2012 Standout
Annual Research Review: Enduring neurobiological effects of childhood abuse and neglect
2016 Standout
Annual Research Review: Prevention of psychosis in adolescents – systematic review and meta‐analysis of advances in detection, prognosis and intervention
2020
Lack of evidence to favor specific preventive interventions in psychosis: a network meta‐analysis
2018
The glucocorticoid receptor: part of the solution or part of the problem?
2006
Phospholipase A2Enzymes: Physical Structure, Biological Function, Disease Implication, Chemical Inhibition, and Therapeutic Intervention
2011 Standout
Improving outcomes of first‐episode psychosis: an overview
2017
Industry sponsorship and research outcome
2017 Standout
Astaxanthin and Docosahexaenoic Acid Reverse the Toxicity of the Maxi-K (BK) Channel Antagonist Mycotoxin Penitrem A
2016
A Systematic Review of Medical Treatments for Children With Autism Spectrum Disorders
2011
Beyond the “at risk mental state” concept: transitioning to transdiagnostic psychiatry
2018
Works of Gregor Berger being referenced
Pituitary volume predicts future transition to psychosis in individuals at ultra-high risk of developing psychosis
2005
Effects of low dose lithium on hippocampal neuropathology in people at ultra-high risk for psychosis
2007
Proton Magnetic Resonance Spectroscopy in First Episode Psychosis and Ultra High-Risk Individuals
2003
Medial temporal lobe glutathione concentration in first episode psychosis: A 1H-MRS investigation
2008
Lithium suppression of tau induces brain iron accumulation and neurodegeneration
2016
Ethyl-Eicosapentaenoic Acid in First-Episode Psychosis. A 1H-MRS Study
2008
Long-Chain ω-3 Fatty Acids for Indicated Prevention of Psychotic Disorders
2010
Omega-3 fatty acid supplementation changes intracellular phospholipase A2 activity and membrane fatty acid profiles in individuals at ultra-high risk for psychosis
2013
Caudate nucleus volume in individuals at ultra-high risk of psychosis: A cross-sectional magnetic resonance imaging study
2010
Risperidone, 2 mg/day vs. 4 mg/day, in First-Episode, Acutely Psychotic Patients
2002
Prediction of Functional Outcome 18 Months After a First Psychotic Episode
2006
Ethyl-Eicosapentaenoic Acid in First-Episode Psychosis
2007
Intervention in Individuals at Ultra-High Risk for Psychosis
2009
A 1H-MRS investigation of the medial temporal lobe in antipsychotic-naïve and early-treated first episode psychosis
2008
Adhesio interthalamica in individuals at high-risk for developing psychosis and patients with psychotic disorders
2008
Structural brain abnormalities in individuals with an at-risk mental state who later develop psychosis
2007
Declining Transition Rate in Ultra High Risk (Prodromal) Services: Dilution or Reduction of Risk?
2007
Randomized Controlled Trial of Interventions for Young People at Ultra High Risk for Psychosis
2010
Omega-3 Fatty Acids Supplementation in Children with Autism: A Double-blind Randomized, Placebo-controlled Pilot Study
2006
Neuroprotective Effects of Low-dose Lithium in Individuals at Ultra-high Risk for Psychosis. A Longitudinal MRI/MRS Study
2012
Clinical trajectories in the ultra-high risk for psychosis population
2018
Randomized Controlled Trial of Interventions for Young People at Ultra-High Risk of Psychosis
2012
Increased calcium-independent phospholipase A2 activity in first but not in multiepisode chronic schizophrenia
2005
Pituitary Volume Predicts Future Transition to Psychosis in Individuals at Ultra-High Risk of Developing Psychosis
2005
Early-onset of symptoms predicts conversion to non-affective psychosis in ultra-high risk individuals
2006
Investigating the effectiveness, safety and tolerability of quetiapine in the treatment of anorexia nervosa in young people: A pilot study
2010
The role of phospholipases A2 in schizophrenia
2006
Neurobiology of early psychosis
2005
Bioactive lipids in schizophrenia
2006
Stage dependant effect of omega-3 fatty acids in emerging psychosis
2011
Prediction of clinical outcomes beyond psychosis in the ultra‐high risk for psychosis population
2020
RANDOMIZED CONTROLLED TRIAL OF INTERVENTIONS FOR YOUNG PEOPLE AT ULTRA-HIGH RISK OF PSYCHOSIS: 12-MONTH OUTCOME
2012
Stress, the Hippocampus and the Hypothalamic-Pituitary-Adrenal Axis: Implications for the Development of Psychotic Disorders
2006
Cocaine and benzoylecgonine in saliva, serum, and urine
1993
Neuroprotection in emerging psychotic disorders
2007
Effect of ω-3 Polyunsaturated Fatty Acids in Young People at Ultrahigh Risk for Psychotic Disorders
2016
Dosing Quetiapine in Drug-Naive First-Episode Psychosis
2008
210. NEURAPRO: A Multi-center RCT of Omega-3 Polyunsaturated Fatty Acids Versus Placebo in Young People at Ultra-High Risk of Psychotic Disorders: Medium-Term Outcome
2017
Ventricle volumes in emerging psychosis. A cross-sectional and longitudinal MRI study
2007
PACE: a specialised service for young people at risk of psychotic disorders
2007
Stress, the hippocampus and the hypothalamic-pituitary-adrenal axis: implications for the development of psychotic disorders
2006
Incipient Neurovulnerability and Neuroprotection in Early Psychosis
2025